This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
Signal Transduction and Targeted Therapy Open Access 27 February 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Frascella E, Rondelli R, Pigazzi M, Zampieron C, Fagioli F, Favre C et al. Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. Leukemia 2004; 18: 1427–1429.
Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009; 23: 1490–1499.
Balgobind BV, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009; 114: 2489–2496.
Pession A, Rizzari C, Putti MC, Masetti R, Casale F, Fagioli F et al. Results of the AIEOP AML 2002/01 study for treatment of children with acute myeloid leukemia. Blood 2009; 114: 22.
Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: Report on 3334 cases from the international MILE study group. J Clin Oncol 2010; 28: 2529–2537.
Den Boer ML, Pieters R . Microarray-based identification of new targets for specific therapies in pediatric leukemia. Curr Drug Targets 2007; 8: 761–764.
Liedtke M, Ayton PM, Somervaille TC, Smith KS, Cleary ML . Self-association mediated by the Ras association 1 domani of AF6 activates the oncogenic potential of MLL-AF6. Blood 2010; 8: 63–70.
Harrison CJ, Hills RK, Moorman AV, Grimwade DJ, Hann I, Webb DK et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010; 28: 2674–2681.
von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28: 2682–2689.
Acknowledgements
This study was supported by grants from the Fondazione Città della Speranza-Padova-Italy (to MP, GB, AZ, SB and LT), from AIRC (Associazione Italiana Ricerca sul Cancro, to GB and GteK), from PRIN/Programmi di ricerca di Rilevante Interesse Nazionale, Rome (to GteK, GB), and the Ministero della Salute (to GB, GteK). We thank MariaGrazia Giacometti and Silvia Disarò for sample collection; Dr Laura Sainati and Dr Samuela Francescato for morphology evaluation; Nancy Jenkins for paper editing.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pigazzi, M., Masetti, R., Bresolin, S. et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia 25, 560–563 (2011). https://doi.org/10.1038/leu.2010.316
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.316
This article is cited by
-
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
Signal Transduction and Targeted Therapy (2023)
-
Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach
Pediatric Research (2021)
-
Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group
Leukemia (2017)
-
Hes1 suppresses acute myeloid leukemia development through FLT3 repression
Leukemia (2015)